G1 Therapeutics to discontinue cancer drug trial, shares plunge 40% (updated)

G1 Therapeutics

13/02/2023 11:38

(Adds trial details, share move)
       Feb 13 (Reuters) - G1 Therapeutics Inc  GTHX.O  said on
Monday it would terminate its cancer therapy study as the
placebo outperformed the drug in its late-stage trial, sending
its shares plunging 40% before the opening bell.
        Although the drug, trilaciclib, achieved its goal in the
trial, the  early anti-tumor efficacy data, including overall
response rate and preliminary measures of survival, favored the
placebo arm, the cancer therapy developer said.
  
        The study was designed to evaluate the efficacy and
safety of the drug administered in addition to triplet therapy
with the first-line therapy in patients with a type of
colorectal cancer.
  
 (Reporting by Sriparna Roy in Bengaluru; Editing by Dhanya Ann
Thoppil and Maju Samuel)
 ((Sriparna.Roy@thomsonreuters.com;))